Project

A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.

Ongoing - recruitment active · 2023 until 2027

Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Ongoing - recruitment active
Start Date
2023
End Date
2027
Financing
Industry
Labels
lung cancer
Brief description/objective